StockData

Addex Therapeutics vs Silo Pharma

ADXN and SILO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADXN and SILO compare

Silo Pharma grew revenue faster over the last twelve months (−25.0% versus −92.6% for Addex Therapeutics).

Silo Pharma scores higher on the StockData Score (2 against 0 for Addex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADXNSILO
Size and price
Market cap–$2.7M
Share price$3.50$1.71
Change, 1 year−58.7%−72.4%
Change, 5 years−97.5%−98.8%
Beta (5Y)1.952.90
Employees33
StockData Score
Total score02 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score01 (better)
Dividend score00
Valuation
P/S–50.2×
P/B–0.6×
Growth
Revenue growth (TTM)−92.6%−25.0% (better)
Revenue growth, 5Y average−61.6%12.0% (better)
EPS growth (TTM)−186%–
Profitability
Gross margin–−14.8%
Operating margin−9391%−8250% (better)
Net margin–−8270%
FCF margin−7244%–
Return on equity–−91.2%
Financial health
Interest coverage−181.0×−112.0× (better)
Current ratio0.765.36 (better)
Altman Z-score–−5.17
Piotroski F-score–4
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%9.0%
Held by insiders15.5%13.8%
Insider net buying, 12 months–$2.1K
Short interest, % of float–1.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.